AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28655692 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline Diphenhydramine group
Number of subjects: 147
Study 24841770 — intervention group
Group type: EXPERIMENTAL
Intervention: Live simulation
Number of subjects: 56
Study 24841770 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality simulation
Number of subjects: 56
Study 24841770 — intervention group
Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 56
Study 23505057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 55
Study 23505057 — intervention group
Group type: COMPARATOR
Intervention: Iron dextran
Number of subjects: 55
Study 21596205 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care model integrating care management (posttraumatic concern elicitation and amelioration, motivational interviewing, and behavioral activation) with cognitive behavioral therapy and pharmacotherapy targeting PTSD
Number of subjects: 207
Study 19164413 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method (CM) with 37% phosphoric acid for 30 seconds
Number of subjects: 100
Study 19164413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus self-etching primer (SEP)
Number of subjects: 100
Study 19164413 — intervention group
Group type: COMPARATOR
Intervention: Machine debonding
Number of subjects: 100
Study 19164413 — intervention group
Group type: COMPARATOR
Intervention: Plier debonding
Number of subjects: 100
Study 19164413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CM and SEP)
Number of subjects: 100
Study 16702196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette advertising and pack displays
Number of subjects: 605
Study 16702196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pack displays only
Number of subjects: 605
Study 16702196 — intervention group
Group type: COMPARATOR
Intervention: No cigarettes (control group)
Number of subjects: 605
Study 16702196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette advertising
Number of subjects: 605
Study 15243144 — intervention group
Group type: EXPERIMENTAL
Intervention: >65% recovery at 7 days
Number of subjects: 1187
Study 15243144 — intervention group
Group type: COMPARATOR
Intervention: <65% recovery at 7 days
Number of subjects: 1187
Study 15243144 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (per 10% increase)
Number of subjects: 1187
Study 11902567 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 0
Study 11902567 — intervention group
Group type: COMPARATOR
Intervention: Sustained release morphine formulations
Number of subjects: 0
Study 8989255 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin alone (10 micrograms)
Number of subjects: 25
Study 8989255 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH alone (100 micrograms)
Number of subjects: 25
Study 8989255 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin and CRH combined
Number of subjects: 25
Study 8989255 — intervention group
Group type: COMPARATOR
Intervention: CRH alone
Number of subjects: 25
Study 8989255 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 25
Study 8989255 — intervention group
Group type: COMPARATOR
Intervention: Standard CRH test
Number of subjects: 25
Study 8203418 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (25 mg daily for 3 months)
Number of subjects: 14
Study 8203418 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 mg monthly for 3 months)
Number of subjects: 14
Study 3307894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily for 6 weeks
Number of subjects: 10
Study 31960058 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin (EPFX) regimen: oral fidaxomicin twice daily for Days 1-5; once daily on alternate days for Days 7-25.
Number of subjects: 14
Study 30426694 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention (weekly nutrition and health classes, exercise sessions 3 days/week)
Number of subjects: 136
Study 30426694 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention
Number of subjects: 136
Study 30426694 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention (in a subsample with prediabetes)
Number of subjects: 136
Study 30426694 — intervention group
Group type: COMPARATOR
Intervention: Comparison control (received laboratory results and general health information)
Number of subjects: 136
Study 26586865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy (six 1-hour sessions, typically 8 participants per group)
Number of subjects: 320
Study 26586865 — intervention group
Group type: COMPARATOR
Intervention: Individual physical therapy (two 1-hour sessions)
Number of subjects: 320
Study 26586865 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy
Number of subjects: 320
Study 26586865 — intervention group
Group type: COMPARATOR
Intervention: Individual physical therapy
Number of subjects: 320
Study 26594272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound simulator training
Number of subjects: 93
Study 26594272 — intervention group
Group type: COMPARATOR
Intervention: Traditional training method via practice on a human model
Number of subjects: 93
Study 24395992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention providing computers, Internet, and training to low SEP individuals
Number of subjects: 312
Study 24395992 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 312
Study 20406311 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase walking
Number of subjects: 572
Study 20406311 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical comorbidity
Number of subjects: 572
Study 20406311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 572
Study 20406311 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity scores
Number of subjects: 572
Study 17541725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 49
Study 17541725 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 49
Study 17541725 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 49
Study 17541725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-eluting stent (TES)
Number of subjects: 49
Study 17541725 — intervention group
Group type: COMPARATOR
Intervention: All stent groups (BMS, SES, PES, TES)
Number of subjects: 49
Study 15728165 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (500 mg/125 mg twice daily)
Number of subjects: 370
Study 15728165 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg twice daily)
Number of subjects: 370
Study 14674739 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contextual intervention
Number of subjects: 1717
Study 14674739 — intervention group
Group type: COMPARATOR
Intervention: Minimum intervention control condition
Number of subjects: 1717
Study 10814607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (250 mmol/day)
Number of subjects: 35
Study 10814607 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (40 mmol/day)
Number of subjects: 35
Study 8730163 — intervention group
Group type: COMPARATOR
Intervention: Occlusive glove worn on one hand for 6 h/day for 14 days (Study A)
Number of subjects: 37
Study 8730163 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive gloves worn on both hands with a cotton glove under the occlusive glove (Study B)
Number of subjects: 37
Study 1879978 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 mg)
Number of subjects: 1210
Study 1879978 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (0.5 mg)
Number of subjects: 1210
Study 7147145 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal medication during labour
Number of subjects: 60
Study 7147145 — intervention group
Group type: COMPARATOR
Intervention: No maternal medication during labour
Number of subjects: 60
Study 30604594 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose plus Metformin (vogmet)
Number of subjects: 187
Study 30604594 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 187
Study 29185490 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 13
Study 29185490 — intervention group
Group type: COMPARATOR
Intervention: Trauma-exposed controls
Number of subjects: 13
Study 26447089 — intervention group
Group type: EXPERIMENTAL
Intervention: SMF (S with fat-containing protein-rich main dishes)
Number of subjects: 9
Study 26447089 — intervention group
Group type: EXPERIMENTAL
Intervention: SMFV (SMF with vegetable dishes)
Number of subjects: 9
Study 26447089 — intervention group
Group type: COMPARATOR
Intervention: S (white rice)
Number of subjects: 9
Study 26447089 — intervention group
Group type: EXPERIMENTAL
Intervention: All test meals
Number of subjects: 9
Study 25501169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 70
Study 22542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of aspirin (100 mg)
Number of subjects: 20
Study 22542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg)
Number of subjects: 20
Study 22542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of aspirin and clopidogrel (AC)
Number of subjects: 20
Study 22542748 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of aspirin with clopidogrel and rabeprazole (10 mg) (ACR)
Number of subjects: 20
Study 19390538 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Allicor daily for 8 weeks
Number of subjects: 84
Study 19390538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg Allicor daily
Number of subjects: 84
Study 19390538 — intervention group
Group type: COMPARATOR
Intervention: 900 mg Kwai daily
Number of subjects: 84
Study 17211695 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy, 3-month course, b.i.d.
Number of subjects: 266
Study 15893086 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual drinking (upper two quartiles)
Number of subjects: 3702
Study 15893086 — intervention group
Group type: COMPARATOR
Intervention: Eight or more drinks per occasion
Number of subjects: 3702
Study 15893086 — intervention group
Group type: COMPARATOR
Intervention: Alcohol effects in women
Number of subjects: 3702
Study 16514819 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 26
Study 10553837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.125% bupivacaine with sufentanil 0.1 microg/mL and clonidine 1 microg/mL at 10 mL/h
Number of subjects: 60
Study 10553837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of the same solution at 5 mL/h plus PCA boluses (2.5 mL/30 min)
Number of subjects: 60
Study 10553837 — intervention group
Group type: COMPARATOR
Intervention: Only PCA boluses (5 mL/30 min) of the same solution
Number of subjects: 60
Study 8909630 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based violence-prevention consultation intervention
Number of subjects: 180
Study 1864637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy (400 mg/Kg every three weeks for one year)
Number of subjects: 0
Study 1864637 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion equivalent volume every three weeks for one year)
Number of subjects: 0
Study 1864637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 0
Study 6750247 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 56
Study 6750247 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 56
Study 30632852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% PHMG phosphate irrigation
Number of subjects: 59
Study 30632852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine irrigation
Number of subjects: 59
Study 30632852 — intervention group
Group type: COMPARATOR
Intervention: Distilled water irrigation
Number of subjects: 59
Study 29945672 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossbow needle therapy, treatment every other day, three times a week, 20 times in total.
Number of subjects: 306
Study 29945672 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, treatment every other day, three times a week, 20 times in total.
Number of subjects: 306
Study 26447872 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC values
Number of subjects: 28
Study 26447872 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC and T2∗ values
Number of subjects: 28
Study 26447872 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 and T2 values
Number of subjects: 28
Study 26447872 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI parameters
Number of subjects: 28
Study 26447872 — intervention group
Group type: EXPERIMENTAL
Intervention: Visibility on T1-weighted images
Number of subjects: 28
Study 24937305 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 20127
Study 22615015 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg plus propofol (M+P)
Number of subjects: 135
Study 22615015 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 135
Study 20530702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (psychological intervention)
Number of subjects: 227
Study 18004123 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine 150 mg/d
Number of subjects: 54
Study 18004123 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg/d
Number of subjects: 54
Study 16045553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 60
Study 16045553 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (hydration and tenoxicam)
Number of subjects: 60
Study 12118650 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of peritoneum
Number of subjects: 100
Study 12118650 — intervention group
Group type: COMPARATOR
Intervention: Non-closure of peritoneum
Number of subjects: 100
Study 10537960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic data from RCTs
Number of subjects: 0
Study 10537960 — intervention group
Group type: EXPERIMENTAL
Intervention: Effectiveness studies
Number of subjects: 0
Study 7757891 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer telephone support program
Number of subjects: 200
Study 7757891 — intervention group
Group type: COMPARATOR
Intervention: Usual services from professionals
Number of subjects: 200
Study 30654196 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair)
Number of subjects: 22
Study 30654196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29547079 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvictimization with EF scores 1.62 or more standard deviations below the mean
Number of subjects: 84
Study 29547079 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvictimization with EF scores at the mean or above
Number of subjects: 84
Study 26846438 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during an eight-week exercise training program
Number of subjects: 110
Study 26846438 — intervention group
Group type: COMPARATOR
Intervention: Medical air during an eight-week exercise training program (sham intervention)
Number of subjects: 110
Study 25282284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 7155
Study 23257428 — intervention group
Group type: COMPARATOR
Intervention: MPO (G-463A) genotype
Number of subjects: 150
Study 23257428 — intervention group
Group type: COMPARATOR
Intervention: NQO1 (C-609T) genotype
Number of subjects: 150
Study 23257428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined gene analysis of MPO and NQO1 wild genotypes
Number of subjects: 150
Study 23257428 — intervention group
Group type: EXPERIMENTAL
Intervention: MPO (G-463A) mutant gene (GA/AA)
Number of subjects: 150
Study 23257428 — intervention group
Group type: EXPERIMENTAL
Intervention: NQO1 (C-609T) mutant gene (TC/TT)
Number of subjects: 150
Study 19146666 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning pillow
Number of subjects: 124
Study 19146666 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 124
Study 19146666 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning pillow (children over 6 years)
Number of subjects: 124
Study 19146666 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control, children over 6 years)
Number of subjects: 124
Study 16947053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenodesis without tenotomy (group 1)
Number of subjects: 22
Study 16947053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenodesis with tenotomy (group 2)
Number of subjects: 22
Study 16947053 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 22
Study 15507172 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511
Study 15507172 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststudy single-agent capecitabine
Number of subjects: 511
Study 15507172 — intervention group
Group type: COMPARATOR
Intervention: Poststudy vinorelbine-containing chemotherapy
Number of subjects: 511
Study 15507172 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing docetaxel and continuing capecitabine
Number of subjects: 511
Study 11838756 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cervical cerclage (n=27)
Number of subjects: 55
Study 11838756 — intervention group
Group type: COMPARATOR
Intervention: Serial weekly evaluations of the cervix by transvaginal ultrasonograms (n=28)
Number of subjects: 55
Study 11838756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 55
Study 9552024 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation without therapeutic intervention
Number of subjects: 12
Study 7914118 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol 10 mg tablets
Number of subjects: 29
Study 7914118 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxodolol 40 mg tablets
Number of subjects: 29
Study 3072783 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg p.o.)
Number of subjects: 9
Study 3072783 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1 8201 (100 mg p.o.)
Number of subjects: 9
Study 3072783 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31672505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-Ceramic Total Hip Arthroplasty (C-O-C THA)
Number of subjects: 133
Study 31672505 — intervention group
Group type: COMPARATOR
Intervention: Ceramic-on-Highly Cross-Linked Polyethylene Total Hip Arthroplasty (C-O-HXLPE THA)
Number of subjects: 133
Study 30156058 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced program (NFN+)
Number of subjects: 57
Study 30156058 — intervention group
Group type: COMPARATOR
Intervention: Standard home visitation program (NFN)
Number of subjects: 57
Study 28782123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh blood (nonleukoreduced RBCs stored for not more than 14 days)
Number of subjects: 199
Study 28782123 — intervention group
Group type: COMPARATOR
Intervention: Old blood (nonleukoreduced RBCs stored for more than 14 days)
Number of subjects: 199
Study 28782123 — intervention group
Group type: COMPARATOR
Intervention: Old blood
Number of subjects: 199
Study 28782123 — intervention group
Group type: COMPARATOR
Intervention: Old blood (as-treated analysis)
Number of subjects: 199
Study 24845604 — intervention group
Group type: COMPARATOR
Intervention: Resistance band training
Number of subjects: 7
Study 23490092 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) treatment group, n=35
Number of subjects: 67
Study 23490092 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=32
Number of subjects: 67
Study 21192310 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI therapy (pantoprazole and omeprazole)
Number of subjects: 126
Study 21192310 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI therapy
Number of subjects: 126
Study 21192310 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of mycophenolate mofetil (1.0 g twice daily)
Number of subjects: 126
Study 21192310 — intervention group
Group type: COMPARATOR
Intervention: Intensified dosing of mycophenolate mofetil (1.5 g twice daily on Days 1‐5, then 1.0 g twice daily)
Number of subjects: 126
Study 18461104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking program (W)
Number of subjects: 30
Study 18461104 — intervention group
Group type: COMPARATOR
Intervention: Conventional management alone (C)
Number of subjects: 30
Study 16603730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 microg bid)
Number of subjects: 30
Study 16603730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14663457 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg) with oral morphine (30 mg)
Number of subjects: 0
Study 14663457 — intervention group
Group type: COMPARATOR
Intervention: Placebo with oral morphine (30 mg)
Number of subjects: 0
Study 14663457 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg) with intravenous morphine (0.15 mg/kg)
Number of subjects: 0
Study 14663457 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intravenous morphine (0.15 mg/kg)
Number of subjects: 0
Study 10997950 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (7.7 g/day)
Number of subjects: 41
Study 10997950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8865958 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 35
Study 8865958 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum gamma-glutamyltransferase (GGT)
Number of subjects: 35
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (slow washout)
Number of subjects: 46
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (slow washout)
Number of subjects: 46
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (fast washout)
Number of subjects: 46